Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Reports Shrinking Revenues, R&D Expenses, Losses for Q4; Wins Pfizer as Customer

NEW YORK, Jan. 29 (GenomeWeb News) - Aclara BioSciences reported decreased revenues, losses, and R&D expenses for the fourth quarter of 2003 yesterday, and said it has won Pfizer as a customer for its eTag assay system.

 

The company's fourth quarter revenues fell to $653,000 from $752,000 a year ago.

 

R&D expenses for the quarter decreased to $3.4 million, from $5 million during the same period last year.

 

Aclara's net losses for the quarter amounted to $3.7 million, or $.10 per share, compared with $7.1 million, or $.20 per share, the year before.

 

As of Dec. 31, 2003, Aclara had cash and short-term investments of $88.4 million.

 

Click here for the full earnings report.

 

Separately, Aclara said that Pfizer will use its eTag assay system at two of its research sites over the next two years.

 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.